Method for determining impurity content in phentolamine mesylate injection by utilizing HPLC (High Performance Liquid Chromatography)

The HPLC method was used to separate and detect impurities B and 5-hydroxymethylfurfural in phentolamine mesylate injection, solving the problem of difficult detection in existing technologies and achieving effective control of drug quality and improved drug safety.

CN118937526APending Publication Date: 2024-11-12JIANGSU LIANHUAN PHARMA
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411122631.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing technologies have failed to effectively control the content of impurity B and 5-hydroxymethylfurfural in phentolamine mesylate injection, affecting drug safety, and lack rapid and accurate detection methods.

Method used

The impurity content in phentolamine mesylate injection was determined by HPLC using an octadecylsilane-bonded silica column, gradient elution, and dual-wavelength detection. Impurity B and 5-hydroxymethylfurfural were detected at 230 nm and 284 nm, respectively.

Benefits of technology

This method enables the effective separation and quantitative analysis of impurity B and 5-hydroxymethylfurfural, improving the controllability of drug quality and enhancing drug safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118937526A_ABST
    Figure CN118937526A_ABST
Patent Text Reader

Abstract

The invention discloses a method for determining the content of impurities in a phentolamine mesylate injection by utilizing HPLC (High Performance Liquid Chromatography), and belongs to the technical field of pharmaceutical analysis. According to the method, a chromatographic column taking C18 as a filling agent is adopted, a sodium heptanesulfonate solution is taken as a mobile phase A, acetonitrile is taken as a mobile phase B, gradient elution is carried out, and the content of the impurity B and the content of 5-hydroxymethylfurfural in the phentolamine mesylate injection are measured. According to the method disclosed by the invention, the phentolamine mesylate, the 5-hydroxymethylfurfural and the impurity B can be effectively separated; meanwhile, the detection result of the content of the impurity B and the 5-hydroxymethylfurfural is not influenced when the chromatographic condition parameters are slightly changed, and the durability is good; the method can be used for rapidly, effectively, accurately and reliably separating and detecting the content of the impurity B and the 5-hydroxymethylfurfural in the phentolamine mesylate injection, and is beneficial to improving the quality controllability of the phentolamine mesylate injection and improving the medication safety of a patient.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of drug analysis, and in particular relates to a method for determining the impurity content in phentolamine mesylate injection by utilizing HPLC. Background Art

[0002] Phentolamine mesylate injection is an α-adrenal receptor blocker. It antagonizes adrenaline and norepinephrine in the blood circulation, dilates blood vessels and reduces peripheral vascular resistance, thereby producing an antagonistic effect on catecholamines and having an excitatory effect on the heart. It is commonly used clinically for 1. diagnosis of pheochromocytoma and treatment of hypertension caused by it, including hypertension during surgical resection. It can also be used to assist in the diagnosis of pheochromocytoma based on the blood pressure response to this product; 2. treatment of left ventricular failure; 3. treatment of norepinephrine intravenous administration spillage to prevent skin necrosis.

[0003] The company's phentolamine mesylate injection was approved for marketing on March 5, 2006, with the approval number of National Medicine Standard H20063706. Anhydrous glucose is a prescription excipient component of the company's injection. During the production process, it may be degraded into 5-hydroxymethylfurfural. Due to its active chemical properties, 5-hydroxymethylfurfural can generate polymers or decompose, triggering and promoting abnormal growth of colonic cysts and having a certain degree of genotoxicity; impurity B is a process impurity introduced by the raw materials. Therefore, the study of 5-hydroxymethylfurfural and impurity B is helpful to control the safety of the drug phentolamine mesylate injection. At present, the pharmacopoeias of various countries have not controlled the impurity B and 5-hydroxymethylfurfural in phentolamine mesylate injection. It is particularly urgent for pharmaceutical manufacturers to study and establish a method for quickly and effectively detecting the content of impurity B and 5-hydroxymethylfurfural in phentolamine mesylate injection. Summary of the invention

[0004] The technical problem solved by the present invention is to provide a high performance liquid chromatography analysis method which has high feasibility, simple and convenient operation process, good applicability, can be widely used in determining the content of impurity B and 5-hydroxymethylfurfural in phentolamine mesylate injection, fully meets the qualitative and quantitative analysis of various impurities in the product, and effectively controls the product quality.

[0005] In order to solve the above technical problems, the technical solution adopted by the present invention is as follows:

[0006] A method for measuring the impurity content in phentolamine mesylate injection by HPLC comprises the following steps:

[0007] 1) Prepare test solution and reference solution;

[0008] 2) Setting the HPLC detection conditions: the chromatographic column is filled with octadecylsilane bonded silica gel, the specification is 4.6 mm×250 mm, the filler particle size is 5 μm, the column temperature is 25-35° C., sodium heptane sulfonate solution is used as mobile phase A, acetonitrile is used as mobile phase B, and gradient elution is performed;

[0009] 3) Accurately pipette the test solution and reference solution respectively, inject them into the liquid chromatograph, and record the chromatogram;

[0010] The impurities in the phentolamine mesylate injection include impurity B and 5-hydroxymethylfurfural; the impurity B is C4H8Cl2N2.

[0011] Preferably, the concentration of the sodium heptane sulfonate solution is 0.01 mol / L, and the preparation process of the sodium heptane sulfonate solution is: take 2g of sodium heptane sulfonate, add 1000mL of water to dissolve it, then add 1mL of triethylamine, and adjust the pH value to 3.0 with phosphoric acid to obtain the sodium heptane sulfonate solution.

[0012] Preferably, in the step 2), the gradient elution conditions are: 0 to 8 min, the volume content of mobile phase A is 80 to 100%, and the volume content of mobile phase B is 0 to 20%; 8 to 8.1 min, the volume content of mobile phase A changes from 80 to 100% to 40 to 60%, and the volume content of mobile phase B changes from 0 to 20% to 60 to 40%; 8.1 to 16 min, the volume content of mobile phase A is 40 to 60%, and the volume content of mobile phase B is 60 to 40%.

[0013] Preferably, in step 2), the chromatographic column is GL Inertsustain C18, and the flow rate of the mobile phase is 0.8-1.2 mL / min.

[0014] Preferably, in step 3), the detection wavelength of the liquid chromatograph is 230 nm and 284 nm.

[0015] Preferably, the injection volume is 10 μL.

[0016] Preferably, in the step 1), the preparation process of the test solution is: taking an appropriate amount of phentolamine mesylate injection, adding a diluent to dissolve and quantitatively diluting to prepare a solution containing 1 mg of phentolamine mesylate per 1 mL, as the test solution;

[0017] The preparation process of the reference solution is as follows: impurity B and 5-hydroxymethylfurfural reference are weighed respectively, dissolved in a diluent, and quantitatively diluted to prepare a reference solution containing 5 μg impurity B and 0.70 μg 5-hydroxymethylfurfural per 1 mL.

[0018] Preferably, the diluent is a mixed solution of 0.01 mol / L sodium heptane sulfonate solution and acetonitrile, wherein the volume ratio of 0.01 mol / L sodium heptane sulfonate solution to acetonitrile is 64:36.

[0019] Preferably, in the step 3), according to the chromatogram, the impurity B at 230nm wavelength shall not be greater than 0.5% based on phentolamine mesylate and the 5-hydroxymethylfurfural at 284nm wavelength shall not be greater than 0.02% based on glucose.

[0020] Beneficial effects: Compared with the prior art, the present invention has the following advantages:

[0021] (1) The present invention adopts dual-wavelength high performance liquid chromatography to detect the contents of impurity B and 5-hydroxymethylfurfural in phentolamine mesylate injection, and can simultaneously analyze the contents of impurity B and 5-hydroxymethylfurfural, which is helpful to control the safety of the drug phentolamine mesylate injection;

[0022] (2) The present invention can achieve effective separation between phentolamine mesylate, 5-hydroxymethylfurfural and impurity B; blank auxiliary materials, blank solvents and other impurities do not interfere with the detection of 5-hydroxymethylfurfural and impurity B; degradation products produced by auxiliary materials and test samples under various destruction conditions do not interfere with the determination of various impurities, and the detection specificity of related substances is good; at the same time, when the chromatographic condition parameters undergo slight changes, the inspection results of the impurity B and 5-hydroxymethylfurfural contents are not affected, and the durability is good;

[0023] (3) The present invention can quickly, effectively, accurately and reliably separate and detect the contents of impurity B and 5-hydroxymethylfurfural in phentolamine mesylate injection, which is beneficial to increasing the quality controllability of phentolamine mesylate injection and improving the safety of medication for patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 is the system suitability chromatogram in Example 1;

[0025] Figure 2 is the standard curve of 5-hydroxymethylfurfural (C6H6O3);

[0026] Figure 3 This is the standard curve of impurity B (C4H8Cl2N2). DETAILED DESCRIPTION

[0027] The present invention will be further illustrated below in conjunction with specific examples. The examples are implemented under the premise of the technical solution of the present invention. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. If specific conditions are not specified in the examples, they are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.

[0028] The impurities related to phentolamine mesylate injection in the following examples are: impurity B (C4H8Cl2N2, a process impurity introduced by the raw materials) and 5-hydroxymethylfurfural (C6H6O3, an impurity of glucose degradation as an auxiliary material).

[0029] Example 1

[0030] (1) Testing conditions

[0031] Instrument: High performance liquid chromatograph Shimadzu LC-20ADXR;

[0032] Detection wavelength: 230nm (impurity B) and 284nm (5-hydroxymethylfurfural);

[0033] Chromatographic column: GL Inertsustain C18, size 4.6mm×250mm, filler particle size 5μm, octadecylsilane bonded silica as filler;

[0034] Mobile phase A: 0.01 mol / L sodium heptane sulfonate solution (containing 0.1% triethylamine, pH adjusted to 3.0 with phosphoric acid);

[0035] Mobile phase B: acetonitrile;

[0036] Gradient elution program: 0-8 min, the volume content of mobile phase A is 85%, and the volume content of mobile phase B is 15%; 8-8.1 min, the volume content of mobile phase A changes from 85% to 50%, and the volume content of mobile phase B changes from 15% to 50%; 8.1-16 min, the volume content of mobile phase A is 50%, and the volume content of mobile phase B is 50%;

[0037] Diluent: a mixed solution containing 0.01 mol / L sodium heptane sulfonate solution (containing 0.1% triethylamine, pH adjusted to 3.0 with phosphoric acid) and acetonitrile, wherein the volume ratio of 0.01 mol / L sodium heptane sulfonate solution to acetonitrile is 64:36;

[0038] Flow rate: 1.0 mL / min;

[0039] Column temperature: 30°C;

[0040] Injection volume: 10 μL.

[0041] (2) Detection steps

[0042] System suitability solution: Weigh appropriate amounts of phentolamine mesylate injection, impurity B and 5-hydroxymethylfurfural reference substance, dissolve them in diluent and quantitatively dilute them to prepare a mixed solution containing 1 mg phentolamine mesylate, 0.5 mg impurity B and 0.1 mg 5-hydroxymethylfurfural per 1 mL, as the system suitability solution;

[0043] Test solution: Take an appropriate amount of phentolamine mesylate injection, dissolve it in a diluent and quantitatively dilute it to make a solution containing 1 mg of phentolamine mesylate per 1 mL as the test solution;

[0044] Reference solution: Weigh impurity B and 5-hydroxymethylfurfural reference respectively, dissolve in diluent and quantitatively dilute to prepare a solution containing 5 μg impurity B and 0.70 μg 5-hydroxymethylfurfural per 1 ml as the reference solution;

[0045] The diluent is 0.01 mol / L sodium heptane sulfonate solution-acetonitrile, and the volume ratio of 0.01 mol / L sodium heptane sulfonate solution to acetonitrile is 64:36; wherein, the preparation process of 0.01 mol / L sodium heptane sulfonate solution is: take 2 g of sodium heptane sulfonate, add 1000 mL of water to dissolve, then add 1 mL of triethylamine, and adjust the pH value to 3.0 with phosphoric acid.

[0046] Accurately measure 10 μL of system suitability solution, reference solution and test solution respectively, inject into liquid chromatograph, record chromatogram, and the result is as follows: Figure 1 shown.

[0047] Depend on Figure 1 It can be seen that under the chromatographic conditions of Example 1, at detection wavelengths of 230 nm and 284 nm, phentolamine mesylate, 5-hydroxymethylfurfural and impurity B can be effectively separated, the separation degree is shown in Table 1, and the solvent peak does not interfere with the determination, which meets the standard.

[0048] Example 2

[0049] The detection method of Example 1 was validated from the aspects of system suitability, destructive test, quantitative limit, detection limit, linear relationship, precision, accuracy and solution stability. The diluents used in the following tests were all 0.01 mol / L sodium heptane sulfonate solution-acetonitrile, and the volume ratio of 0.01 mol / L sodium heptane sulfonate solution to acetonitrile was 64:36; wherein, 0.01 mol / L sodium heptane sulfonate solution (containing 0.1% triethylamine, pH value adjusted to 3.0 with phosphoric acid).

[0050] (1) System applicability

[0051] Take 5-hydroxymethylfurfural reference substance, dissolve it in diluent and dilute it to make a localization solution containing 10 μg 5-hydroxymethylfurfural per 1 mL;

[0052] Take the impurity B reference substance, dissolve it in the diluent and dilute it to make a positioning solution containing 10 μg of impurity B per 1 mL;

[0053] Take the phentolamine mesylate reference substance, dissolve it in a diluent and dilute it to make a localization solution containing 10 μg of phentolamine mesylate per 1 mL;

[0054] Take appropriate amounts of phentolamine mesylate injection, impurity B and 5-hydroxymethylfurfural reference substance, add diluent to dissolve and dilute to prepare a mixed solution containing 1 mg phentolamine mesylate, 0.5 mg impurity B and 0.1 mg 5-hydroxymethylfurfural per 1 mL, as the system suitability solution.

[0055] Table 1: Impurity location and separation table

[0056]

[0057] As shown in Table 1, the main component (phentolamine mesylate), 5-hydroxymethylfurfural and impurity B can be effectively separated at wavelengths of 230 nm and 284 nm, and the blank excipient and blank solvent do not interfere with the determination.

[0058] (2) Destructive testing

[0059] Take 30 vials of phentolamine mesylate injection and mix them well to prepare the destructive test solution.

[0060] Undamaged solution: Take 1 mL of the mixed sample and place it in a 10 mL volumetric flask, then add diluent to dilute to the mark.

[0061] Acid destruction solution: Take 1 mL of the mixed sample and place it in a 10 mL volumetric flask, add 0.5 mL of 1 mol / L hydrochloric acid, leave it at room temperature for 3 h, add 0.5 mL of 1 mol / L sodium hydroxide to neutralize it, and add diluent to dilute to the scale.

[0062] Alkali destruction solution: Take 1 mL of the mixed sample and place it in a 10 mL volumetric flask, add 0.5 mL of 1 mol / L sodium hydroxide, leave it at room temperature for 1 hour, add 0.5 mL of 1 mol / L hydrochloric acid to neutralize it, and add diluent to dilute to the scale.

[0063] Oxidative destruction solution: Take 1 mL of the mixed sample and place it in a 10 mL volumetric flask, add 0.5 mL of 3% hydrogen peroxide, leave it at room temperature for 3 hours, and dilute it to the scale with diluent.

[0064] Light-destruction solution: Take 5 mL of the mixed sample and place it in a quartz tube. Place it under ultraviolet light for 10 min. Take 1 mL and place it in a 10 mL volumetric flask. Add diluent and dilute to the scale.

[0065] High temperature destruction solution: Take 5 vials of phentolamine mesylate injection, place them at 100℃ for 6 hours, take them out and mix them well, take 1mL and place it in a 10mL volumetric flask, and add diluent to dilute to the scale.

[0066] Under various destruction conditions, after deducting the peaks of solvents and excipients, no 5-hydroxymethylfurfural and impurity B peaks were detected in the test samples. No degradation impurities were detected in samples destroyed by acid, oxidation, and light. In samples destroyed by alkali and high temperature, impurity A peak was detected with a retention time of 14.6 min, which did not interfere with the detection of 5-hydroxymethylfurfural and impurity B. No other impurity peaks were detected, indicating good specificity.

[0067] (3) Limit of quantification and limit of detection test

[0068] Take appropriate amount of impurity B and 5-hydroxymethylfurfural reference substance, dissolve and dilute with diluent to make a solution containing 0.5μg impurity B and 0.070μg 5-hydroxymethylfurfural per 1mL. The quantitative limit (S / N≥10) and detection limit (S / N≥3) were measured by stepwise dilution method. The results are shown in Table 2.

[0069] Table 2: Limits of detection and limits of quantitation

[0070]

[0071] (4) Injection precision

[0072] Take appropriate amounts of impurity B and 5-hydroxymethylfurfural reference substance, add diluent to dissolve and dilute to prepare a solution containing 5 μg impurity B and 0.70 μg 5-hydroxymethylfurfural per 1 mL. Under the chromatographic conditions of Example 1, the sample was injected 6 times continuously. The injection precision results are shown in Table 3.

[0073] Table 3: Injection precision results

[0074]

[0075] As shown in Table 3, the RSD of the peak area of ​​5-hydroxymethylfurfural in the six injection precision samples was 0.17%, and the RSD of the peak area of ​​impurity B was 0.18%, both of which were less than 2.0%, indicating that the injection precision of the two components was good.

[0076] (5) Solution stability

[0077] Take appropriate amounts of impurity B and 5-hydroxymethylfurfural reference substance, add diluent to dissolve and dilute to make a solution containing 5 μg impurity B and 0.70 μg 5-hydroxymethylfurfural per 1 mL, as the reference substance solution.

[0078] Take an appropriate amount of this product, add diluent to dissolve and quantitatively dilute to make a solution containing 1 mg of phentolamine mesylate per 1 mL as the test solution.

[0079] Under the chromatographic conditions of Example 1, the sample was injected within 26 hours to investigate its intra-day stability. The stability results are shown in Table 4.

[0080] Table 4: Solution stability results

[0081]

[0082]

[0083] As shown in Table 4, the RSD of the peak area of ​​5-hydroxymethylfurfural in the reference solution was 0.27%, and the RSD of the peak area of ​​impurity B was 0.72%. Neither 5-hydroxymethylfurfural nor impurity B was detected in the test solution. The results show that the reference solution and the test solution have good stability within 26 hours.

[0084] (6) Linearity and range

[0085] Impurity B and 5-hydroxymethylfurfural were taken, dissolved and diluted with a diluent to prepare a stock solution containing 10 μg of impurity B and 1.4 μg of 5-hydroxymethylfurfural per 1 mL as a linear stock solution. Under the chromatographic conditions of Example 1, solutions were prepared at 4%, 10%, 50%, 100%, and 200% limits (as shown in Table 5), and a standard curve was drawn. The results are shown in Tables 6 and Figure 2-3 shown.

[0086] Table 5: Dilution preparation of linear solutions at various concentrations

[0087]

[0088] Table 6: Linearity test results

[0089] name Regression curve Correlation coefficient Range (μg / mL) Impurity B Y=1.3328X-0.0168 1.0000 0.2067~10.3345 5-Hydroxymethylfurfural Y=7.9617X+0.0020 1.0000 0.0276~1.3815

[0090] Depend on Figure 2-3 As shown in Table 6, the impurity B and 5-hydroxymethylfurfural are linear within the limit concentration range of 4% to 200%, and r is greater than 0.999.

[0091] (7) Repeatability

[0092] Take an appropriate amount of this product, dissolve it with a diluent and dilute it quantitatively to make a solution containing 1 mg of phentolamine mesylate per 1 mL as the test solution; take an appropriate amount of impurity B and 5-hydroxymethylfurfural reference substance, dissolve it with a diluent and dilute it to make a solution containing 5 μg of impurity B and 0.70 μg of 5-hydroxymethylfurfural per 1 mL as the reference substance solution. Take the above solutions and inject them separately, repeat the determination for 6 times, and the results are shown in Table 7.

[0093] Table 7: Repeatability test table

[0094]

[0095] It can be seen from Table 7 that 5-hydroxymethylfurfural and impurity B were not detected in the test solution, indicating that the two components of 5-hydroxymethylfurfural and impurity B have good repeatability.

[0096] (8) Intermediate precision

[0097] Different operators tested the contents of 5-hydroxymethylfurfural and impurity B in the same batch of samples at different times and with different instruments according to the repeatability test method. The results are shown in Table 8.

[0098] Table 8: Intermediate precision test table

[0099]

[0100] It can be seen from Table 8 that 5-hydroxymethylfurfural and impurity B were not detected in the test solution. This is consistent with the repeatability results, indicating that the intermediate precision is good.

[0101] (9) Recovery rate

[0102] Reference solution: Weigh impurity B and 5-hydroxymethylfurfural reference respectively, add diluent to dissolve and quantitatively dilute to make a solution containing 5 μg impurity B and 0.70 μg 5-hydroxymethylfurfural per 1 ml as the reference solution.

[0103] Take appropriate amount of impurity B and 5-hydroxymethylfurfural reference substance, weigh accurately, add diluent to dilute to make a solution containing 3.5 μg 5-hydroxymethylfurfural and 25 μg impurity B per 1 mL as the recovery rate stock solution.

[0104] Accurately pipette an appropriate amount of phentolamine mesylate injection, add 0.5 times the amount of 3% hydrogen peroxide solution for oxidation treatment for 10 minutes, then accurately pipette the above recovery rate stock solution and dilute it to prepare a solution containing 1 mg / mL phentolamine mesylate, 5-hydroxymethylfurfural and impurity B at 50%, 100% and 200% of the limit concentration. Prepare 3 portions of each concentration, and prepare a background solution for background deduction in the recovery calculation. Take 10 μL of the above reference solution, background solution and test solution, inject them separately, and record the chromatogram attached. Record the peak area and calculate the recovery. The results of the sample recovery determination are shown in Tables 9 and 10, respectively.

[0105] Table 9: Impurity B recovery rate determination results

[0106]

[0107] Table 10: 5-Hydroxymethylfurfural recovery rate determination results

[0108]

[0109]

[0110] As shown in Tables 9 and 10, the average recovery rate of 5-hydroxymethylfurfural (n=9) is 96.22% with an RSD of 0.54%; the average recovery rate of impurity B (n=9) is 99.66% with an RSD of 0.25%, indicating that the recovery rates of 5-hydroxymethylfurfural and impurity B are good and the method has good accuracy.

[0111] (10) Robustness of HPLC method for related substances

[0112] Referring to the guidance for validation of analytical methods for drug quality standards in the General Chapter 9101 of the Chinese Pharmacopoeia, a durability test was conducted on the impurity B and 5-hydroxymethylfurfural content in phentolamine mesylate injection. The system suitability solution was injected, and the column temperature (±2°C), flow rate (±0.05mL / min), initial proportion of mobile phase (±2%), mobile phase pH (±0.05), and chromatographic column were changed respectively. The durability study project was conducted on the chromatographic conditions of Example 1. The specific results are shown in Table 11 below.

[0113] Table 11: Durability test results

[0114]

[0115] As shown in Table 11, changing the column temperature (±2°C), flow rate (±0.05mL / min), initial proportion of mobile phase (±2%), mobile phase pH (±0.05), and chromatographic column has no significant effect on the test results, indicating that this method has good durability.

[0116] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A method for determining the impurity content in phentolamine mesylate injection using HPLC, It is characterized in that The following steps are involved: 1) Prepare test solution and reference solution; 2) Setting the HPLC detection conditions: the chromatographic column is filled with octadecylsilane bonded silica gel, the specification is 4.6 mm×250 mm, the filler particle size is 5 μm, the column temperature is 25-35° C., sodium heptane sulfonate solution is used as mobile phase A, acetonitrile is used as mobile phase B, and gradient elution is performed; 3) Accurately pipette the test solution and reference solution respectively, inject them into the liquid chromatograph, and record the chromatogram; The impurities in the phentolamine mesylate injection include impurity B and 5-hydroxymethylfurfural; the impurity B is C 4 H 8 Cl 2 N 2 .

2. The method for determining the impurity content in phentolamine mesylate injection by HPLC according to claim 1, It is characterized in that The concentration of the sodium heptane sulfonate solution is 0.01 mol / L. The preparation process of the sodium heptane sulfonate solution is as follows: 2 g of sodium heptane sulfonate is dissolved in 1000 mL of water, and then 1 mL of triethylamine is added. The pH value is adjusted to 3.0 with phosphoric acid to obtain the sodium heptane sulfonate solution.

3. The method for determining the impurity content in phentolamine mesylate injection by HPLC according to claim 1, It is characterized in that In the step 2), the gradient elution conditions are: 0-8 min, the volume content of mobile phase A is 80-100%, and the volume content of mobile phase B is 0-20%; 8-8.1 min, the volume content of mobile phase A changes from 80-100% to 40-60%, and the volume content of mobile phase B changes from 0-20% to 60-40%; 8.1-16 min, the volume content of mobile phase A is 40-60%, and the volume content of mobile phase B is 60-40%.

4. The method for determining the impurity content in phentolamine mesylate injection by HPLC according to claim 1, It is characterized in that In the step 2), the chromatographic column is GL Inertsustain C18, and the flow rate of the mobile phase is 0.8-1.2 mL / min.

5. The method for determining the impurity content in phentolamine mesylate injection by HPLC according to claim 1, It is characterized in that In the step 3), the detection wavelengths of the liquid chromatograph are 230 nm and 284 nm.

6. The method for determining the impurity content in phentolamine mesylate injection by HPLC according to claim 1, It is characterized in that The injection volume was 10 μL.

7. The method for determining the impurity content in phentolamine mesylate injection by HPLC according to claim 1, It is characterized in that In the step 1), the preparation process of the test solution is as follows: take an appropriate amount of phentolamine mesylate injection, add a diluent to dissolve and quantitatively dilute to prepare a solution containing 1 mg of phentolamine mesylate per 1 mL, as the test solution; The preparation process of the reference solution is as follows: impurity B and 5-hydroxymethylfurfural reference are weighed respectively, dissolved in a diluent, and quantitatively diluted to prepare a reference solution containing 5 μg impurity B and 0.70 μg 5-hydroxymethylfurfural per 1 mL.

8. The method for determining the impurity content in phentolamine mesylate injection by HPLC according to claim 7, It is characterized in that The diluent is a mixed solution of 0.01 mol / L sodium heptane sulfonate solution and acetonitrile, wherein the volume ratio of 0.01 mol / L sodium heptane sulfonate solution to acetonitrile is 64:

36.

9. The method for determining the impurity content in phentolamine mesylate injection by HPLC according to claim 1, It is characterized in that In the step 3), according to the chromatogram, the impurity B at a wavelength of 230 nm shall not be greater than 0.5% by peak area calculated by external standard method based on phentolamine mesylate; Calculated on the basis of glucose, the 5-hydroxymethylfurfural at a wavelength of 284 nm shall not be greater than 0.02%.

Citation Information

Patent Citations

  • Method for synthesizing phentolamine mesylate

    CN101463009A

  • Method for synthesizing phentolamine mesylate

    CN115368310A

  • Preparation method of phentolamine mesylate

    CN116768798A